Achieving a more complete picture of the spectrum of events that lead to dysregulated STAT3 signaling in T cell malignancies and the precise molecular consequences of the augmented STAT3 signal may enable development of future therapeutic modalities for STAT3 driven cancers. This evidence concerns the gene STAT3 and cancer.